Ticker: CVM

CEL-SCI Corporation (NYSE: CVM) - Q3 2025 quick take What's happening inside: Management is advancing a planned 212‑patient confirmatory registration study for Multikine while continuing to fund operations with equity raises. The company reduced operating losses vs. prior year but remains unprofi...